News articles about Bellicum Pharmaceuticals (NASDAQ:BLCM) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 46.3986670472716 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Zacks: Brokerages Anticipate Bellicum Pharmaceuticals, Inc. (BLCM) Will Announce Earnings of -$0.65 Per Share (americanbankingnews.com)
- Stock Price Performance Review for Bellicum Pharmaceuticals, Inc … - Jonesboro Recorder (jonesbororecorder.com)
- Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer - GlobeNewswire (press release) (globenewswire.com)
- Parkwood LLC Sells 1031 Shares of Leucadia National Corporation (NYSE:LUK) (campdesrecrues.com)
Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 10.88 on Tuesday. Bellicum Pharmaceuticals has a 52 week low of $9.71 and a 52 week high of $23.11. The firm has a 50-day moving average price of $11.88 and a 200-day moving average price of $12.49. The stock’s market cap is $360.16 million.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by $0.10. Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 63.42%. The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.09 million. During the same period in the prior year, the business earned ($0.56) EPS. The business’s revenue for the quarter was up 39.1% compared to the same quarter last year. On average, equities research analysts predict that Bellicum Pharmaceuticals will post ($2.84) EPS for the current year.
Several research analysts recently weighed in on the company. BidaskClub lowered Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, July 6th. Cantor Fitzgerald set a $32.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, June 27th. Ladenburg Thalmann Financial Services set a $31.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Finally, Jefferies Group LLC dropped their price target on Bellicum Pharmaceuticals from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, May 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $28.43.
In other Bellicum Pharmaceuticals news, VP Ken Moseley sold 13,823 shares of Bellicum Pharmaceuticals stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the sale, the vice president now owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Alan A. Musso sold 6,311 shares of Bellicum Pharmaceuticals stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $12.24, for a total value of $77,246.64. The disclosure for this sale can be found here. Insiders sold a total of 30,571 shares of company stock worth $367,295 in the last three months. Company insiders own 23.30% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
